|
1
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cantwell-Dorris ER, O'Leary JJ and Sheils
OM: BRAFV600E: Implications for carcinogenesis and molecular
therapy. Mol Cancer Ther. 10:385–394. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Behling F, Barrantes-Freer A, Skardelly M,
Nieser M, Christians A, Stockhammer F, Rohde V, Tatagiba M,
Hartmann C, Stadelmann C and Schittenhelm J: Frequency of BRAF
V600E mutations in 969 central nervous system neoplasms. Diagn
Pathol. 11:552016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schindler G, Capper D, Meyer J, Janzarik
W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C,
Hasselblatt M, et al: Analysis of BRAF V600E mutation in 1,320
nervous system tumors reveals high mutation frequencies in
pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar
pilocytic astrocytoma. Acta Neuropathol. 121:397–405. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 world health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosenblum MK, Erlandson RA and Budzilovich
GN: The lipid-rich epithelioid glioblastoma. Am J Surg Pathol.
15:925–934. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Akimoto J, Namatame H, Haraoka J and Kudo
M: Epithelioid glioblastoma: A case report. Brain Tumor Pathol.
22:21–27. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rodriguez FJ, Scheithauer BW, Giannini C,
Bryant SC and Jenkins RB: Epithelial and pseudoepithelial
differentiation in glioblastoma and gliosarcoma: A comparative
morphologic and molecular genetic study. Cancer. 113:2779–2789.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gasco J, Franklin B, Fuller GN, Salinas P
and Prabhu S: Multifocal epithelioid glioblastoma mimicking
cerebral metastasis: Case report. Neurocirugia (Astur). 20:550–554.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tanaka S, Nakada M, Hayashi Y, Nakada S,
Sawada-Kitamura S, Furuyama N, Suzuki T, Kamide T, Hayashi Y, Yano
S and Hamada J: Epithelioid glioblastoma changed to typical
glioblastoma: The methylation status of MGMT promoter and 5-ALA
fluorescence. Brain Tumor Pathol. 28:59–64. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kleinschmidt-DeMasters BK, Aisner DL and
Foreman NK: BRAF VE1 immunoreactivity patterns in epithelioid
glioblastomas positive for BRAF V600E mutation. Am J Surg Pathol.
39:528–540. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kleinschmidt-DeMasters BK, Aisner DL,
Birks DK and Foreman NK: Epithelioid GBMs show a high percentage of
BRAF V600E mutation. Am J Surg Pathol. 37:685–698. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Capper D, Preusser M, Habel A, Sahm F,
Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H and
von Deimling A: Assessment of BRAF V600E mutation status by
immunohistochemistry with a mutation-specific monoclonal antibody.
Acta Neuropathol. 122:11–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Colomba E, Hélias-Rodzewicz Z, Von
Deimling A, Marin C, Terrones N, Pechaud D, Surel S, Côté JF,
Peschaud F, Capper D, et al: Detection of BRAF p.V600E mutations in
melanomas: comparison of four methods argues for sequential use of
immunohistochemistry and pyrosequencing. J Mol Diagn. 15:94–100.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dvorak K, Aggeler B, Palting J, McKelvie
P, Ruszkiewicz A and Waring P: Immunohistochemistry with the
anti-BRAF V600E (VE1) antibody: Impact of pre-analytical conditions
and concordance with DNA sequencing in colorectal and papillary
thyroid carcinoma. Pathology. 46:509–517. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ilie M, Long E, Hofman V, Dadone B,
Marquette CH, Mouroux J, Vignaud JM, Begueret H, Merlio JP, Capper
D, et al: Diagnostic value of immunohistochemistry for the
detection of the BRAFV600E mutation in primary lung adenocarcinoma
Caucasian patients. Ann Oncol. 24:742–748. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ida CM, Vrana JA, Rodriguez FJ, Jentoft
ME, Caron AA, Jenkins SM and Giannini C: Immunohistochemistry is
highly sensitive and specific for detection of BRAF V600E mutation
in pleomorphic xanthoastrocytoma. Acta Neuropathol Commun.
1:202013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ritterhouse LL and Barletta JA: BRAF V600E
mutation-specific antibody: A review. Semin Diagn Pathol.
32:400–408. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lo MC, Paterson A, Maraka J, Clark R,
Goodwill J, Nobes J, Garioch J, Moncrieff M, Rytina E and Igali L:
A UK feasibility and validation study of the VE1 monoclonal
antibody immunohistochemistry stain for BRAF-V600E mutations in
metastatic melanoma. Br J Cancer. 115:223–227. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gierke M, Sperveslage J, Schwab D,
Beschorner R, Ebinger M, Schuhmann MU and Schittenhelm J: Analysis
of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion
transcript status in central nervous system tumors supports
pediatric tumor classification. J Cancer Res Clin Oncol.
142:89–100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gupta K, Orisme W, Harreld JH, Qaddoumi I,
Dalton JD, Punchihewa C, Collins-Underwood R, Robertson T,
Tatevossian RG and Ellison DW: Posterior fossa and spinal
gangliogliomas form two distinct clinicopathologic and molecular
subgroups. Acta Neuropathol Commun. 2:182014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qaddoumi I, Orisme W, Wen J, Santiago T,
Gupta K, Dalton JD, Tang B, Haupfear K, Punchihewa C, Easton J, et
al: Genetic alterations in uncommon low-grade neuroepithelial
tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and
align with morphology. Acta Neuropathol. 131:833–845. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ballester LY, Fuller GN, Powell SZ, Sulman
EP, Patel KP, Luthra R and Routbort MJ: Retrospective analysis of
molecular and immunohistochemical characterization of 381 primary
brain tumors. J Neuropathol Exp Neurol. 76:179–188. 2017.PubMed/NCBI
|
|
24
|
Alexandrescu S, Korshunov A, Lai SH,
Dabiri S, Patil S, Li R, Shih CS, Bonnin JM, Baker JA, Du E, et al:
Epithelioid glioblastomas and anaplastic epithelioid pleomorphic
xanthoastrocytomas-same entity or first cousins? Brain Pathol.
26:215–223. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kleinschmidt-DeMasters BK, Alassiri AH,
Birks DK, Newell KL, Moore W and Lillehei KO: Epithelioid versus
rhabdoid glioblastomas are distinguished by monosomy 22 and
immunohistochemical expression of INI-1 but not claudin 6. Am J
Surg Pathol. 34:341–354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tanaka S, Nakada M, Nobusawa S, Suzuki SO,
Sabit H, Miyashita K and Hayashi Y: Epithelioid glioblastoma
arising from pleomorphic xanthoastrocytoma with the BRAF V600E
mutation. Brain Tumor Pathol. 31:172–176. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Broniscer A, Tatevossian RG, Sabin ND,
Klimo P Jr, Dalton J, Lee R, Gajjar A and Ellison DW: Clinical,
radiological, histological and molecular characteristics of
paediatric epithelioid glioblastoma. Neuropathol Appl Neurobiol.
40:327–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dahiya S, Emnett RJ, Haydon DH, Leonard
JR, Phillips JJ, Perry A and Gutmann DH: BRAF-V600E mutation in
pediatric and adult glioblastoma. Neuro Oncol. 16:318–319. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Takahashi Y, Akahane T, Sawada T, Ikeda H,
Tempaku A, Yamauchi S, Nishihara H, Tanaka S, Nitta K, Ide W, et
al: Adult classical glioblastoma with a BRAF V600E mutation. World
J Surg Oncol. 13:1002015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sperveslage J, Gierke M, Capper D,
Honegger J, Sipos B, Beschorner R and Schittenhelm J: VE1
immunohistochemistry in pituitary adenomas is not associated with
BRAF V600E mutation. Acta Neuropathol. 125:911–912. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sosman JA, Kim KB, Schuchter L, Gonzalez
R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ,
Flaherty KT, et al: Survival in BRAF V600-mutant advanced melanoma
treated with vemurafenib. N Engl J Med. 366:707–714. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chamberlain MC: Salvage therapy with BRAF
inhibitors for recurrent pleomorphic xanthoastrocytoma: A
retrospective case series. J Neurooncol. 114:237–240. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee EQ, Ruland S, LeBoeuf NR, Wen PY and
Santagata S: Successful treatment of a progressive BRAF
V600E-mutated anaplastic pleomorphic xanthoastrocytoma with
vemurafenib monotherapy. J Clin Oncol. 34:e87–e89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Robinson GW, Orr BA and Gajjar A: Complete
clinical regression of a BRAF V600E-mutant pediatric glioblastoma
multiforme after BRAF inhibitor therapy. BMC Cancer. 14:2582014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rush S, Foreman N and Liu A: Brainstem
ganglioglioma successfully treated with vemurafenib. J Clin Oncol.
31:e159–e160. 2013. View Article : Google Scholar : PubMed/NCBI
|
